Companies
Cr

Cradle

Generative AI protein engineering platform

Founded2021
HQZurich, Switzerland / Amsterdam, Netherlands
StagePlatform
Total Funding$100M+
cradle.bio
SharePostShare

Overview

Cradle provides a generative AI platform for protein engineering that enables scientists to design improved proteins in a fraction of the time required by traditional methods. The platform is used across therapeutics, diagnostics, food, chemicals, and agriculture by clients including Novo Nordisk and Johnson & Johnson. With 31 molecules in development on its platform, Cradle has established itself as a leading AI tool for industrial protein optimization.

Focus areas

Generative Chemistry, Foundation Models, Platform


Funding

$100M+

Total raised

Series B2024-11

$73M

Led by IVP

Series AIndex Ventures
$24M2024-02
Series BIVP
$73M2024-11
Notable investors

IVP · Index Ventures · Kindred Capital


Technology

Generative AI platform for protein engineering. The system designs and optimizes protein sequences for improved function, stability, and manufacturability across multiple application areas. Cradle's in-house wet lab generates proprietary data to train and validate its models.

Platforms & Tools
Generative protein designProtein optimization engineWet lab validation

Leadership

Stef van Grieken

CEO & Co-Founder


Partnerships
Novo NordiskProtein engineering for therapeutic development
Johnson & JohnsonProtein engineering collaboration

Similar companies

Get updates on Cradle

We'll notify you when we publish updates about Cradle.